Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.50 |
| ▸ | DRD5 | P21918 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5449773 | 0.80 | PRMT5 (0.49) | DRD2PRMT5WDR77HDAC1HDAC6 | |
| SCHEMBL5455348 | 0.80 | LMNA (0.46) | DRD2DRD1DRD5DRD3PRMT5 | |
| SCHEMBL8496974 | 0.79 | KCNH2 (0.54) | DRD2DRD1DRD5DRD3 | |
| SCHEMBL5447851 | 0.79 | ALDH1A1 (0.54) | DRD2HDAC1HDAC6 | |
| SCHEMBL5445261 | 0.78 | NPC1 (0.57) | DRD2 | |
| SCHEMBL5451891 | 0.78 | MTNR1A (0.48) | DRD2PRMT5WDR77HDAC1HDAC6 | |
| SCHEMBL5454487 | 0.77 | HTR5A (0.50) | DRD2DRD3 | |
| SCHEMBL5753631 | 0.77 | DRD2 (0.53) | DRD2DRD1DRD5DRD3HDAC1 | |
| SCHEMBL5456113 | 0.77 | DRD2 (0.44) | DRD2DRD1DRD5DRD3PRMT5 | |
| SCHEMBL1132759 | 0.77 | DRD2 (0.54) | DRD2DRD1DRD5DRD3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | DRD2 1065/4885DRD1 1296/4885DRD5 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.